These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 23859348)

  • 1. Co-enzyme Q10 and idebenone use in Friedreich's ataxia.
    Parkinson MH; Schulz JB; Giunti P
    J Neurochem; 2013 Aug; 126 Suppl 1():125-41. PubMed ID: 23859348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idebenone in Friedreich's ataxia.
    Tonon C; Lodi R
    Expert Opin Pharmacother; 2008 Sep; 9(13):2327-37. PubMed ID: 18710357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Friedreich's Ataxia: disease mechanisms, antioxidant and Coenzyme Q10 therapy.
    Cooper JM; Schapira AH
    Biofactors; 2003; 18(1-4):163-71. PubMed ID: 14695932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic evaluation of idebenone.
    Becker C; Bray-French K; Drewe J
    Expert Opin Drug Metab Toxicol; 2010 Nov; 6(11):1437-44. PubMed ID: 20955109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study.
    Rustin P; von Kleist-Retzow JC; Chantrel-Groussard K; Sidi D; Munnich A; Rötig A
    Lancet; 1999 Aug; 354(9177):477-9. PubMed ID: 10465173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deferiprone and idebenone rescue frataxin depletion phenotypes in a Drosophila model of Friedreich's ataxia.
    Soriano S; Llorens JV; Blanco-Sobero L; Gutiérrez L; Calap-Quintana P; Morales MP; Moltó MD; Martínez-Sebastián MJ
    Gene; 2013 Jun; 521(2):274-81. PubMed ID: 23542074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial dysfunction in Friedreich's ataxia: from pathogenesis to treatment perspectives.
    Lodi R; Rajagopalan B; Bradley JL; Taylor DJ; Crilley JG; Hart PE; Blamire AM; Manners D; Styles P; Schapira AH; Cooper JM
    Free Radic Res; 2002 Apr; 36(4):461-6. PubMed ID: 12069111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring cardiac function during idebenone therapy in Friedreich's ataxia.
    Giovanni DS; Valeria P; Bahaa F; Majid AF
    Curr Pharm Des; 2015; 21(4):479-83. PubMed ID: 25483949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes in Friedreich's ataxia after withdrawal from idebenone.
    Cook A; Boesch S; Heck S; Brunt E; Klockgether T; Schöls L; Schulz A; Giunti P
    Acta Neurol Scand; 2019 Jun; 139(6):533-539. PubMed ID: 30887496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia.
    Hausse AO; Aggoun Y; Bonnet D; Sidi D; Munnich A; Rötig A; Rustin P
    Heart; 2002 Apr; 87(4):346-9. PubMed ID: 11907009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for clinical trials of selenium as an antioxidant for the treatment of the cardiomyopathy of Friedreich's ataxia.
    Fryer MJ
    Med Hypotheses; 2002 Feb; 58(2):127-32. PubMed ID: 11812188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Friedreich's ataxia: idebenone treatment in early stage patients.
    Artuch R; Aracil A; Mas A; Colomé C; Rissech M; Monrós E; Pineda M
    Neuropediatrics; 2002 Aug; 33(4):190-3. PubMed ID: 12368988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of antioxidants in Friedreich's ataxia treatment.
    Rustin P
    Expert Opin Investig Drugs; 2003 Apr; 12(4):569-75. PubMed ID: 12665413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Friedreich's ataxia: coenzyme Q10 and vitamin E therapy.
    Cooper JM; Schapira AH
    Mitochondrion; 2007 Jun; 7 Suppl():S127-35. PubMed ID: 17485244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic approaches for the treatment of Friedreich's ataxia.
    Strawser CJ; Schadt KA; Lynch DR
    Expert Rev Neurother; 2014 Aug; 14(8):949-57. PubMed ID: 25034024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia.
    Seznec H; Simon D; Monassier L; Criqui-Filipe P; Gansmuller A; Rustin P; Koenig M; Puccio H
    Hum Mol Genet; 2004 May; 13(10):1017-24. PubMed ID: 15028670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular insights into Friedreich's ataxia and antioxidant-based therapies.
    Rötig A; Sidi D; Munnich A; Rustin P
    Trends Mol Med; 2002 May; 8(5):221-4. PubMed ID: 12067631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient attenuation of Friedreich's ataxia (FRDA) cardiomyopathy by modulation of iron homeostasis-human induced pluripotent stem cell (hiPSC) as a drug screening platform for FRDA.
    Lee YK; Lau YM; Ng KM; Lai WH; Ho SL; Tse HF; Siu CW; Ho PW
    Int J Cardiol; 2016 Jan; 203():964-71. PubMed ID: 26625322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurophysiological evaluation in children with Friedreich's ataxia.
    Sival DA; du Marchie Sarvaas GJ; Brouwer OF; Uges DR; Verschuuren-Bemelmans CC; Maurits NM; Brunt ER; van der Hoeven JH
    Early Hum Dev; 2009 Oct; 85(10):647-51. PubMed ID: 19775837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia.
    Velasco-Sánchez D; Aracil A; Montero R; Mas A; Jiménez L; O'Callaghan M; Tondo M; Capdevila A; Blanch J; Artuch R; Pineda M
    Cerebellum; 2011 Mar; 10(1):1-8. PubMed ID: 20865357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.